Pay in 4 interest-free payments of $7.39 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Key takeaways Retatrutide isn't approved yet and isn't expected to launch in the UK until at least mid-2026 In clinical trials, target doses ranged from 0.5mg to 12mg weekly, with the most common being 4mg, 8mg, 9mg and 12mg Different dosing schedules were tested, with most people starting at 2mg and escalating every 4 weeks The 12mg dose produced the most weight loss (up to 28.7% after 68 weeks) Starting at 2mg rather than 4mg helped reduce side effects during escalation First to know Get an email the day retatrutide launches in the UK
Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised double-lind, phase 3a trial
Tirzepatide and Back Pain: Understanding the Connection The following blog post is for entertainment and informational purposes only
Oncogenic activities of IDH1/2 mutations: from epigenetics to cellular signaling
US$ 24.00
US$ 22.98
US$ 22.76
US$ 23.28
